Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A. C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R. A. Stahel, J. VansteenkisteD. De Ruysscher*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalLung Cancer
Volume133
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • Chemotherapy
  • Radiotherapy
  • Cancer immunotherapy
  • Immune checkpoint inhibitors
  • PD-1 inhibitor
  • Nivolumab
  • Combination treatment

Cite this